Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Income from Continuing Operations (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Income from Continuing Operations for 10 consecutive years, with 12165000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 134.04% year-over-year to 12165000.0, compared with a TTM value of 83229000.0 through Dec 2025, up 178.88%, and an annual FY2025 reading of 83229000.0, up 178.88% over the prior year.
  • Income from Continuing Operations was 12165000.0 for Q4 2025 at Zevra Therapeutics, up from 544000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 74707000.0 in Q2 2025 and bottomed at 35739000.0 in Q4 2024.
  • Average Income from Continuing Operations over 5 years is 5329150.0, with a median of 4857500.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations surged 622.12% in 2021, then plummeted 674.39% in 2024.
  • Year by year, Income from Continuing Operations stood at 2703000.0 in 2021, then skyrocketed by 340.58% to 6503000.0 in 2022, then tumbled by 405.89% to 19892000.0 in 2023, then plummeted by 79.67% to 35739000.0 in 2024, then surged by 134.04% to 12165000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ZVRA at 12165000.0 in Q4 2025, 544000.0 in Q3 2025, and 74707000.0 in Q2 2025.